How do you comprehensively analyze a stock?

1. Profitability Return on Equity (ROE) = Net Profit / Shareholders' Equity (Net Assets) Return on Total Assets (ROA) = Net Profit / Total Assets 2. Growth Capability Growth can be assessed from both revenue and asset perspectives. From the revenue perspective, focus on: Revenue Growth Rate, Operating Profit Growth Rate, and Net Profit Growth Rate. From the asset perspective, examine: Total Asset Growth Rate and Net Asset Growth Rate. From a company’s growth standpoint, it must not only generate profits but also sustain and expand profitability year after year—only such companies can deliver excess returns. 3. Operational Efficiency This measures how frequently a company conducts business transactions within a given period. For example, with identical foot traffic, Xiao Ming’s hotpot restaurant achieves a significantly higher table-turnover rate than Xiao Gang’s, resulting in markedly higher revenue. Hence, asset turnover ratio is critically important. The higher the turnover ratio, the stronger the company’s operational capability—and the more efficient its use of capital or inventory. 4. Solvency This refers to a company’s ability to repay debts when they mature; failure to do so renders it a defaulting entity. Solvency is typically evaluated using three metrics: Current Ratio, Quick Ratio, and Short-Term Solvency. A current ratio above 2 generally indicates strong operational health; below 1 suggests poor operational capacity and potential difficulty meeting short-term creditor obligations. The quick ratio is considered normal around 1—meaning for every 1 unit of current liabilities, the company holds 1 unit of liquid assets to cover them, ensuring reliable short-term solvency. A quick ratio below 1 signals short-term repayment risk. A quick ratio far exceeding 1 may indicate weak cash management. Short-term solvency primarily reflects the relationship between current assets and current liabilities: if current assets sufficiently cover current liabilities, the company demonstrates robust solvency. Short-Term Solvency = Net Operating Cash Flow / Current Liabilities. Generally, a ratio near 1 is appropriate. This metric is not ‘the higher, the better’, since cash yields low returns; excessively high cash and cash equivalents on the cash flow statement suggest inefficient cash utilization and subpar profitability. III. Code Analysis This is a Jupyter Notebook file (stock_filter.ipynb), comprising the following key steps: 1. Import dependencies: pandas, numpy, requests, and the custom sharetop package. 2. Initialize the Sharetop client: connect to the Sharetop data service using an authentication token. 3. Define field mappings: map English data field names to Chinese display names for clarity in downstream presentation. 4. Encapsulate data-fetching functions: _fetch_df() standardizes calls to various Sharetop financial statement APIs and returns structured DataFrames. 5. Core processing function run(): accepts a stock code and sector, retrieves four financial statements (key metrics, income statement, cash flow statement, balance sheet), merges them, and computes year-on-year (YoY) growth rates and derived ratios (e.g., R&D expense ratio, debt ratio). 6. Data cleaning and presentation: rename merged DataFrame columns into Chinese, and add a 'Company Type' classification—determined by sign combinations of net cash flows from operating, investing, and financing activities (e.g., 'Cash Cow', 'Startup'). 7. Advanced styled tables: apply custom function advanced_financial_analysis() to generate HTML tables with conditional color formatting for intuitive analysis. 8. Visualization: leverage plotly to plot growth-rate line charts (code partially imported but not fully shown).

Weekly Deep Dive | Leader Harmonic Drive: All the money the entire market trusts for humanoid robots resides in its market cap.

Breaking it down more concretely: Q1 net profit attributable to shareholders: ¥0.33 billion, up +61.2% YoY; Q2 single-quarter net profit: ¥0.37 billion, up +12.9% YoY. Although Q2’s growth rate slowed, the first half still delivered over 30% growth. The company manufactures harmonic drive gearboxes—the critical component inside robotic joints that converts high-speed motor rotation into precise, controlled motion. Every time a humanoid robot lifts its arm or closes its fingers, that motion is enabled by a harmonic drive. A single humanoid robot contains dozens of such joints—anywhere from 10 to 30. Leader’s position in the global harmonic drive industry is best captured by its own mid-year report: “The Company is the world’s only manufacturer capable of fully self-supplying all precision harmonic drive components.” It handles everything in-house—from raw materials and rough machining, through precision finishing, to final assembly—relying on no external suppliers. In plain terms: delivery timelines are fully under its control, and there remains room to further reduce costs. II. Growth Is Real—but So Are Its Costs The primary driver of H1 growth, per the mid-year report, was: “increased market share in the industrial robotics sector and substantial expansion of embodied AI robot business.” By product category: • Harmonic drives & metal components: ¥288 million (82.7% of total revenue), gross margin 32.8%; • Electromechanical integrated products: ¥55 million (15.7%), gross margin 29.8%; • Others: 1.6%. Electromechanical integration refers to pre-assembled joint modules combining harmonic drives, motors, and encoders—customers simply install them directly. This segment is handled by its subsidiary Kaixuan Intelligent, generating ¥54 million in H1 revenue. This trend reflects growing preference among robot OEMs for ready-to-install joints over individual components—but its gross margin is slightly lower than selling harmonic drives alone. Most notably: gross margin for H1 stood at 32.26%, down 2.5 percentage points from 34.77% YoY. Why the decline? As stated in broker research reports and widely echoed across the industry: harmonic drive unit prices have plummeted—from over ¥3,000 per unit in earlier years to around ¥800 for certain models today. To enable mass production of humanoid robots, integrators aggressively squeeze pricing on joint modules—the largest cost item. Companies like LaiFu, Zhongda Lid, and Leader have all been caught in this pressure. Price compression is an unavoidable step to transition humanoid robots from exhibition pieces to commercial products—but during this phase, gross margins inevitably take the first hit. One additional point worth noting: operating cash flow for H1 was a net outflow of ¥0.17 billion, versus a net inflow last year. The company explains this as stemming from received bank acceptance bills being endorsed to purchase long-term assets, and some payments to suppliers being made via issued notes payable. In essence: incoming funds were mostly promissory notes—not actual cash—and those notes were immediately redeployed as payment. This isn’t necessarily negative—but warrants close monitoring, especially whether cash collections recover in Q4. III. How Expensive Is It? Unpacking Three Future Scenarios Closing price on September 30: ¥273.75; total market cap: ¥50.187 billion. Full-year 2025 net profit attributable to shareholders: ¥124 million → P/E = 404x. Even assuming H2 replicates H1’s performance, full-year 2026 net profit would reach ~¥140 million → P/E remains 358x; P/S = 87.9x. That is, the market values this company—which generated just ¥570 million in annual revenue—at ¥50.2 billion.

Balchem Corp Revenue Breakdown – HAN:BL9B

Sep 29, 2026

Balchem Corporation reported total revenue of 883.06 million EUR last year, with its Human Nutrition and Health segment leading performance. The United States served as the primary regional market, contributing 646.61 million EUR to the total.

TradingView

2026-03-22

BCPC SEC Filings - Balchem Corp 10-K, 10-Q, 8-K Forms

2026-03-27

Balchem Reports €0.0 Million NonCurrent Deferred Revenue as of December 2025

2026-04-09

Balchem Corp. Stock Valuation Revised Amid Competitive FMCG Landscape

2026-04-11

Balchem Reports $581 Million Gross Property, Plant and Equipment as of December 2025

2026-04-16

Zinc Methionine Chelates Market Forecast Report 2025-2033 Featuring Alltech, Balchem, Titan Biotech, UNO VETCHEM, Zinpro, Chaitanya Biologicals, Chengdu Chelation Biology, JH, Novus, Priya